An-Luo-Hua-Xian Pill Improves the Regression of Liver Fibrosis in Chronic Hepatitis B Patients Treated with Entecavir
Yiqi Liu, Chi Zhang, Jiawen Li, Lihua Cao, Zhanqing Zhang, Weifeng Zhao, Qing-Hua Shang, Dazhi Zhang, Anlin Ma, Qing Xie, Honglian Gui, Guo Zhang, Yingxia Liu, Jia Shang, Shi-Bin Xie, Jun Li, Xuqing Zhang, Zhiqiang Zou, Yuping Chen, Zong Zhang, Mingxiang Zhang, Jun Cheng, Fuchun Zhang, Lihua Huang, Jiabin Li, Meng Qing-hua, Haibin Yu, Yuqiang Mi, Yanzhong Peng, Zhijin Wang, Liming Chen, Fanping Meng, Wanhua Ren, Lang Bai, Yilan Zeng, Rong Fan, Xian-Zhi Lou, Weifeng Liang, Hui Liu, Hui Zhuang, Hong Zhao, Guiqiang Wang
Abstract
Background and Aims: Chronic hepatitis B (CHB) can cause liver fibrosis and lead to cirrhosis and cancer. As the effectiveness of antiviral therapy to reverse liver fibrosis is limited, We aimed to evaluate the effect of An-Luo-Hua-Xian pill (ALHX) on fibrosis regression in CHB patients treated with entecavir (ETV). Methods: Treatment-naïve patients with CHB were randomly treated with ETV alone or combined with ALHX (ETV+ALHX) between October 1, 2013 and December 31, 2020. Demographic, laboratory, and liver histology data before and after 78 weeks of treatment were collected. The Ishak fibrosis score (F) was used and fibrosis regression required a decrease in F of ≥1 after treatment. Results: =0.031). Conclusions: ETV combined with ALHX increased liver fibrosis regression in CHB patients.